MedTrace Logo

Phase I Clinical Trial of 68Ga-NOTA-SNA002

NCT05989997 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-09-16

No results posted yet for this study

Summary

The clinical trial was a single-center, dose-increasing, open trial.In this clinical trial, 68Ga-NOTA-SNA002 was injected intravenously to observe its safety tolerance, radiation absorption dose, distribution characteristics, etc. in patients with solid tumors.

Conditions

Interventions

DRUG

68Ga-NOTA-SNA002

68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.

Sponsors & Collaborators

  • SmartNuclide Biopharma

    lead INDUSTRY

Principal Investigators

  • Hongcheng Shi, Doctor · Department of Nuclear Medicine, Zhongshan Hospital, Fudan University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-11-08
Completion
2024-11-08
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05989997 on ClinicalTrials.gov